Key result
Long-term administration of telmisartan prevented impaired vasorelaxation and decreased soluble guanylyl cyclase expression in mesenteric arteries of an animal model of metabolic syndrome.
Why the study?
Does telmisartan improve vasorelaxation function in an animal model of metabolic syndrome?
Does telmisartan improve vasorelaxation function in an animal model of metabolic syndrome?
Absolute Event Rate: 7.3% vs 8.01%
p-value: p=<0.05
Telmisartan prevents vasorelaxation dysfunction in a rat model of metabolic syndrome by reducing peroxynitrite-mediated denaturation of soluble guanylyl cyclase.
May preserve vascular function in metabolic syndrome models; hypothesis-generating from Level 5 animal data and should not change practice.
We have previously reported that peroxynitrite is involved in dysfunction of nitric oxide (NO)-mediated vasorelaxation in SHR/NDmcr-cp rats (SHR-cp), which display typical symptoms of metabolic syndrome. This study investigated whether peroxynitrite is actually generated in the vascular wall with angiotensin II-induced NADPH-oxidase activation, thus contributing to the dysfunction. In isolated mesenteric arteries of male 18-week-old SHR-cp, relaxations in response to acetylcholine and sodium nitroprusside were impaired compared with that in Wistar-Kyoto rats. This impaired relaxation was not restored by treatment with apocynin, an NADPH-oxidase inhibitor. Protein expression of endothelial NO synthase increased while that of soluble guanylyl cyclase (sGC) decreased in the artery. We observed increased production of superoxide anions and peroxynitrite from the artery and their inhibition by apocynin, and also increased contents of nitrotyrosine, a biomarker of peroxynitrite, in mesenteric arteries and angiotensin II in aortas. Long-term (8 weeks) administration of telmisartan, an angiotensin II type 1-receptor antagonist, prevented the impaired vasorelaxation, decreased sGC expression and increased nitrotyrosine content in mesenteric arteries. These findings suggest that in the vascular wall of SHR-cp, peroxynitrite is continually produced by the reaction of NO with NADPH oxidase-derived superoxide via angiotensin II and gradually denatures sGC protein, leading to vasorelaxation dysfunction.
No takes yet. Share an insight, caveat, or question.
Kagota et al. (2009) studied Metabolic syndrome (animal model) (n=36). Telmisartan vs. Vehicle (0.5% CMC) or WKY rats was evaluated on Vasorelaxation response to acetylcholine (pEC50) (p=<0.05). Long-term administration of telmisartan prevented impaired vasorelaxation and decreased soluble guanylyl cyclase expression in mesenteric arteries of an animal model of metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: